Herantis Pharma Oyj (HRTIS) - Cash Flow Conversion Efficiency

Latest as of June 2025: -1.937x

Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has a cash flow conversion efficiency ratio of -1.937x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.39 Million ≈ $-3.96 Million USD) by net assets (€1.75 Million ≈ $2.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Herantis Pharma Oyj - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Herantis Pharma Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HRTIS total liabilities for a breakdown of total debt and financial obligations.

Herantis Pharma Oyj Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Herantis Pharma Oyj ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Melhus Sparebank OL:MELG	0.110x
Tune Protect Group Bhd KLSE:5230	0.004x
HRS Co. Ltd KQ:036640	-0.004x
HSS Engineers Bhd KLSE:0185	-0.057x
Bright Sheland International Co Ltd TWO:4556	0.038x
Cingulate Inc NASDAQ:CING	-1.434x
Optivision Technology TWO:3666	0.002x
Boreo Oyj HE:BOREO	0.095x

Annual Cash Flow Conversion Efficiency for Herantis Pharma Oyj (2012–2024)

The table below shows the annual cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Herantis Pharma Oyj market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€-243.00K ≈ $-284.09K	€-6.54 Million ≈ $-7.65 Million	26.934x	+2845.91%
2023-12-31	€4.73 Million ≈ $5.53 Million	€-4.64 Million ≈ $-5.42 Million	-0.981x	-100.66%
2022-12-31	€-60.28K ≈ $-70.48K	€-8.94 Million ≈ $-10.46 Million	148.365x	+927.89%
2021-12-31	€554.30K ≈ $648.04K	€-9.93 Million ≈ $-11.61 Million	-17.921x	-1488.32%
2020-12-31	€7.59 Million ≈ $8.87 Million	€-8.56 Million ≈ $-10.01 Million	-1.128x	+64.95%
2019-12-31	€1.85 Million ≈ $2.16 Million	€-5.96 Million ≈ $-6.97 Million	-3.219x	-107.70%
2018-12-31	€-89.29K ≈ $-104.39K	€-3.73 Million ≈ $-4.36 Million	41.801x	+6678.70%
2017-12-31	€4.09 Million ≈ $4.78 Million	€-2.60 Million ≈ $-3.04 Million	-0.635x	+67.04%
2016-12-31	€1.57 Million ≈ $1.84 Million	€-3.04 Million ≈ $-3.55 Million	-1.928x	-56.32%
2015-12-31	€6.00 Million ≈ $7.01 Million	€-7.40 Million ≈ $-8.65 Million	-1.233x	-514.33%
2014-12-31	€21.72 Million ≈ $25.39 Million	€-4.36 Million ≈ $-5.10 Million	-0.201x	+89.26%
2013-12-31	€120.00K ≈ $140.29K	€-224.21K ≈ $-262.13K	-1.868x	-101.18%
2012-12-31	€-3.37K ≈ $-3.94K	€-533.42K ≈ $-623.62K	158.097x	--

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$54.84 Million

€46.91 Million EUR

Market Cap Rank

#21646 Global

#108 in Finland

Share Price

€1.77

Change (1 day)

+1.14%

52-Week Range

€1.23 - €2.78

All Time High

€10.10